Should tranexamic acid be administered as an infusion for acute intracerebral hemorrhage in a patient with chronic kidney disease?

Tranexamic Acid Should NOT Be Routinely Used for Acute Intracerebral Hemorrhage in CKD Patients

Based on the most recent and highest quality evidence, tranexamic acid infusion is not recommended for acute spontaneous intracerebral hemorrhage (ICH), regardless of whether the patient has chronic kidney disease. The 2025 French guidelines explicitly state that tranexamic acid showed no efficacy in reducing hematoma progression in non-traumatic cerebral hemorrhage, and the European Stroke Organisation does not recommend its use for cerebral hemorrhage 1.

Key Evidence Against TXA in Acute ICH

The evidence is clear and consistent:

• The TICH-NOAC study found no efficacy of tranexamic acid in reducing hematoma size progression in patients with non-traumatic cerebral hemorrhage on anticoagulants 1
• The European Stroke Organisation explicitly does not recommend tranexamic acid for cerebral hemorrhage on vitamin K antagonists 1
• The 2022 AHA/ASA guidelines note that further studies are needed to determine if TXA benefits ICH patients, indicating insufficient evidence for routine use 2
• The 2014 ESO guidelines found no evidence supporting hemostatic drugs including tranexamic acid for acute spontaneous ICH 3

The most recent meta-analysis (2025) including the STOP-MSU trial demonstrated that TXA does not significantly reduce hematoma growth or improve clinical outcomes in spontaneous ICH 4. The TICH-2 trial (2018), the largest randomized controlled trial with 2,325 participants, showed no significant difference in functional status at 90 days despite early administration 5.

Critical Safety Concerns in CKD Patients

The presence of CKD creates additional contraindications and risks that make TXA use even more problematic:

Dosing Complications

The FDA label mandates dose reduction in renal impairment 6:

• Serum creatinine 1.36-2.83 mg/dL: 10 mg/kg twice daily
• Serum creatinine 2.83-5.66 mg/dL: 10 mg/kg daily
• Serum creatinine >5.66 mg/dL: 10 mg/kg every 48 hours OR 5 mg/kg every 24 hours

Neurotoxicity Risk

Neurotoxicity is the most common manifestation of TXA toxicity in CKD patients 7. The FDA label explicitly warns that TXA may cause seizures, with dose adjustments required for renal dysfunction 6. Case reports document severe neurotoxicity in peritoneal dialysis and stage 4 CKD patients when dosing was not adjusted 7.

Thromboembolic Risk

The FDA label warns that TXA increases thromboembolic risk, including cerebral thrombosis 6. Prolonged administration (>1 day) or delayed administration (>8 hours) significantly increases thromboembolic events 8. CKD patients already have elevated thrombotic risk, compounding this concern.

FDA Contraindication

The FDA explicitly contraindicates TXA in patients with subarachnoid hemorrhage, citing anecdotal evidence of cerebral edema and cerebral infarction 6. While this specifically addresses subarachnoid hemorrhage, it demonstrates recognized neurotoxicity concerns in intracranial bleeding.

When TXA IS Indicated (Not Applicable Here)

The 2025 guidelines clearly delineate where TXA does work 9:

• Severe trauma with hemorrhage (CRASH-2 protocol: 1g bolus within first hour, then 1g over 8 hours)
• Traumatic brain injury (CRASH-3 trial, within 3 hours of injury)
• Post-partum hemorrhage
• Emergency cardiac surgery

Critically, administration must occur within 3 hours of injury onset—beyond this window, TXA may actually increase mortality from hemorrhage 9.

Clinical Algorithm for This Scenario

For a CKD patient with acute spontaneous ICH:

1. Do NOT administer tranexamic acid for the ICH itself
2. Focus on blood pressure management and supportive care per AHA/ASA guidelines 2
3. If the patient is on anticoagulants, reverse anticoagulation urgently (PCCs for warfarin, idarucizumab for dabigatran) 1
4. Assess renal function to guide other medication dosing
5. Monitor for hematoma expansion with serial CT imaging within 24 hours 2

Important Caveats

The only scenario where TXA might be considered is if the ICH occurred in the context of acute trauma (not spontaneous ICH), and only if:

• Within 3 hours of injury
• Dose adjusted for renal function per FDA guidelines
• Close monitoring for seizures and neurotoxicity
• Recognition that evidence is from traumatic brain injury, not spontaneous ICH

Chronic renal impairment is considered a relative contraindication to TXA due to reports of ureteric clots and acute renal failure from cortical necrosis 10. While one case series showed safe use in polycystic kidney disease with hematuria 10, this does not translate to ICH management.

The evidence consistently demonstrates that tranexamic acid provides no benefit for spontaneous ICH and carries significant risks, particularly in CKD patients where neurotoxicity is common and dosing adjustments are essential 1, 2, 3, 4, 5, 7.